Issue Date: August 1, 2011
… And Alnylam To MIT
Alnylam Pharmaceuticals and MIT have developed new nanoparticles for the systemic delivery of RNAi therapeutics. They created core-shell nanoparticles using high-throughput polymer synthesis and then screened for those having the best properties for intracellular delivery. “Continued progress in delivery of RNAi therapeutics requires broad-based efforts around novel lipids, conjugates, and polymers,” says Kevin Fitzgerald, Alnylam’s senior director of research. The partners published their findings in the Proceedings of the National Academy of Sciences USA (DOI: 10.1073/pnas.1106379108).
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society